Clinical Trials

31 enrolled

Biliary Tract Neoplasms

NCT03572400 2024-04-19

Neoadjuvant CCRT With Gemcitabine/Durvalumab (MEDI4736) Followed by Adjuvant Gemcitabine/Durvalumab(MEDI4736) in Resectable or Borderline Resectable Pancreatic Cancer

71 enrolled

Pancreatic Neoplasms

NCT04447092 2024-04-19

Pembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic Cancer

77 enrolled

Pancreatic Neoplasms

NCT06233864 2024-04-17

A Study of the Treatment of Disitamab Vedotin in Patients With Locally Advanced or Metastatic Pancreatic Cancer

63 enrolled

Pancreatic Neoplasms

NCT06364826 2024-04-15

Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal Carcinoma

60 enrolled

Nasopharyngeal Carcinoma

NCT05048524 2024-03-27

Peri-operative SLOG for Localized Pancreatic Cancer

64 enrolled

Pancreatic Neoplasms

NCT04739670 2024-03-01

BELLA

31 enrolled

Recurrence, Triple Negative Breast Neoplasms

NCT02098954 2023-12-27

Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers

Carcinoma, Non-Small-Cell Lung

NCT04902261 2023-09-01

Tislelizumab Combined With Nab-paclitaxel and Gemcitabine for Recurrent Pancreatic Cancer

140 enrolled

Pancreatic Neoplasms

NCT04262804 2023-08-22

A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC

123 enrolled

Breast Cancer Metastatic

NCT05979298 2023-08-07

Efficacy of Plasmid Elenagen in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Cancer

Gynecologic

Ovarian Neoplasms

NCT03567720 2023-06-01

Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC

65 enrolled

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT05795920 2023-04-03

Utidelone Injection Combined With Gemcitabine in First-line Chemotherapy for Unresectable Advanced Pancreatic Cancer

92 enrolled

Pancreatic Neoplasms

NCT05097209 2023-03-23

Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma

200 enrolled

Nasopharyngeal Carcinoma

NCT05774028 2023-03-17

Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) in the Treatment of Untreated Early Non-upper Respiratory Tract or Advanced Extranodal NK/T-cell Lymphoma

50 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT05549466 2023-02-08

Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC

84 enrolled

Nasopharyngeal Carcinoma

NCT04405622 2023-02-06

Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma.

21 enrolled

Nasopharyngeal Carcinoma

NCT05672537 2023-01-05

Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk

70 enrolled

Cholangiocarcinoma

NCT05647330 2022-12-12

Hydroxychloroquine Combined With Gemcitabine in the Treatment of Advanced Non-small Cell Lung Cancer

55 enrolled

Lung Neoplasms

NCT05640791 2022-12-07

Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer

Resectable Biliary Tract Cancer

NCT03574402 2022-12-06

TRUMP

400 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05634564 2022-12-05

Concurrent Chemoradiotherapy Combined With Immunotherapy in Patients With Potentially Resectable Pancreatic Cancer

62 enrolled

Pancreatic Neoplasms

NCT05350943 2022-10-18

HAIC Combined With Toripalimab and Donafenib for Advanced BTC

70 enrolled

Biliary Tract Adenocarcinoma

NCT05410197 2022-10-12

Envofolimab and Lenvatinib Combined With Gemcitabine Plus Cisplatin for Advanced BTC as First-Line Treatment(ENLIGHTEN)

43 enrolled

Advanced Biliary Tract Cancer

NCT03487016 2022-09-08

FOOTPATH

270 enrolled

Neoplasm Metastasis, Pancreatic Neoplasms

NCT05401279 2022-08-18

Bladder Sparing Treatment of Tislelizumab, Gemcitabine and Cisplatin for Patients With PD-L1 Positive Muscle Invasive Bladder Cancer

20 enrolled

Genitourinary

Urothelial Carcinoma Bladder

NCT04297267 2022-07-22

nonpCR GP

Triple Negative Breast Neoplasms

NCT05448885 2022-07-08

Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma

50 enrolled

Nasopharyngeal Carcinoma

NCT05448183 2022-07-07

An Observational Real World Study on the Efficacy and Safety of Toripalimab Injection Combined With TACE in the Treatment of Extrahepatic Cholangiocarcinoma

45 enrolled

Cholangiocarcinoma

NCT05346146 2022-04-26

A Prospective, Single-arm, Exploratory Clinical Study of Sintilimab Injection in Combination With Paclitaxel (Albumin-bound) and Gemcitabine in Translational Therapy in Patients With Unresectable Locally Advanced Pancreatic Cancer.

20 enrolled

Unresectable Locally Advanced Pancreatic Cancer

NCT02341911 2022-04-20

TNBC

150 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04745975 2022-04-20

Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer

Triple Negative Breast Neoplasms

NCT05298020 2022-03-28

Envafolimab Combined With Endostar and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer

20 enrolled

Advanced Pancreatic Cancer

NCT05186558 2022-03-07

Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL

54 enrolled

Neoplasms by Histologic Type, Lymphoma, Large B-Cell, Diffuse

NCT05254899 2022-02-24

Anti-PD-1 Antibody and P-GEMOX Chemotherapy Combined With Radiotherapy in High-risk Early-Stage ENKTL

54 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT05185869 2022-01-11

SHR6390 Plus Nab-paclitaxel and Gemcitabine in Advanced/Metastatic Pancreatic Cancer

58 enrolled

Pancreatic Neoplasms

NCT01595061 2021-12-29

Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Cancer of the Vulva

57 enrolled 11 charts

Gynecologic

Vulvar Neoplasms

NCT04089150 2021-10-22

MASTERPLAN

120 enrolled

Pancreatic Neoplasms

NCT05047991 2021-09-17

Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma

153 enrolled

Pancreatic Cancer Non-resectable

NCT03467178 2021-09-05

MITO29

119 enrolled

Recurrence

NCT05030077 2021-09-01

Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma

53 enrolled

Genitourinary

Carcinoma, Transitional Cell, Urogenital Neoplasms

NCT04586465 2021-08-24

DYNAPET

23 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04917250 2021-06-08

GPED for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma

15 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT04909775 2021-06-02

Chemotherapy Combined With Tislelizumab as Bladder Sparing Option for Patients With Muscle Invasive Bladder Cancer

Muscle-Invasive Bladder Carcinoma

NCT02822157 2021-01-29

CLIO

160 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial

NCT04692051 2020-12-31

A Phase II Study for Nab-paclitaxel Plus Cisplatin vs Gemcitabine Plus Cispatin as First Line Chemotherapy in Advanced Biliary Tract Cancer

Biliary Tract Neoplasms

NCT04681911 2020-12-23

Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer

71 enrolled

Breast Neoplasms

NCT04668976 2020-12-21

A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma

Colorectal Neoplasms, Cholangiocarcinoma

NCT04571489 2020-10-01

A Phase II Study of Gimatecan (ST1481) in Locally Advanced or Metastatic Pancreatic Cancer

60 enrolled